Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of AR ...

By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal diseases by modulating activation of the complement cascade. About the AROC3-1001 Phase 1/2a Study ...

A U.S. Navy pilot went aboard Charles de Gaulle with the C-2A Greyhound to document flight ops aboard ‘The Only Foreign Aircraft Carrier We Can Land On’. “I filmed this video in 2016 when my ...

A C-2A Greyhound launches from the USS Theodore Roosevelt in 2017. C-2As are back on west coast carrier decks after the grounding of their replacement, the CMV-22B. (US Navy) The US Navy (USN) has ...